Hemispherx Biopharma says FDA authorizes study using aspirin and flagship drug ampligen to treat prostate cancer

06:04 EDT 13 May 2019 | Proactive Investors

The Phase 2 study will be carried out at the Roswell Park Comprehensive Cancer Center in Buffalo and involve up to 60 patients

More From BioPortfolio on "Hemispherx Biopharma says FDA authorizes study using aspirin and flagship drug ampligen to treat prostate cancer"